Circulating Tumour Cells in Patients With Peritoneal Metastases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04083547|
Recruitment Status : Recruiting
First Posted : September 10, 2019
Last Update Posted : September 10, 2019
|Condition or disease||Intervention/treatment|
|Circulating Tumor Cell Peritoneal Metastases Hyperthermic Intraperitoneal Chemotherapy||Diagnostic Test: iCellate|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Cirkulerande Tumörceller Hos Patienter Med Bukhinnespridda tumörer|
|Actual Study Start Date :||October 17, 2017|
|Estimated Primary Completion Date :||October 1, 2019|
|Estimated Study Completion Date :||December 31, 2019|
All patients undergoing HIPEC will asked to join this prospective study.
Diagnostic Test: iCellate
New method of circulating tumour cell detection and capture.
- Prognostic value [ Time Frame: 2 year. ]Prediction of survival and recurrence according to the occurrence of CTCs.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04083547
|Contact: Peter Cashin, MD PhD||+46 firstname.lastname@example.org|
|Akademiska Sjukhuset (Uppsala University hospital)||Recruiting|
|Uppsala, Sweden, 75185|
|Contact: Peter Cashin, M.D. Ph.D +46 18 6174304 email@example.com|
|Principal Investigator: Peter Cashin, MD, PhD|
|Sub-Investigator: Christer Ericsson, MD, PhD|